(P004) A Comparison of Postmastectomy Radiation Therapy (PMRT) With Protons vs Photons

Publication
Article
OncologyOncology Vol 30 No 4_Suppl_1
Volume 30
Issue 4_Suppl_1

Protons for postmastectomy radiation therapy, particularly in cases of challenging anatomy, result in decreased dose to normal structures compared with photon plans, with acceptable acute toxicity. Dose escalation after double-scattered proton should be used with caution to avoid skin toxicity.

Jennifer Vogel, MD, Lilie Lin, MD, Katie Shillington, CMD, Geraldine Shammo, CMD, Maura Kirk, MS, Stefan Both, PhD, Gary Freedman, MD; University of Pennsylvania

PURPOSE: PMRT improves survival of patients with high-risk breast cancer but may cause cardiac and pulmonary morbidity. We evaluated acute toxicity from proton beam postmastectomy radiation therapy (PMRT) in patients with reconstruction and/or challenging anatomy, and dosimetrically compared proton and photon plans.


METHODS: Patients treated with double-scattered proton (DS-PT) PMRT were enrolled in an institutional review board (IRB)-approved registry. Three-dimensional (3D) conformal photon ± electron or intensity-modulated radiation therapy (IMRT) (Rapid Arc) comparison plans were generated for each patient, depending on which best suited patient anatomy. Wilcoxon paired t-test was used for statistical comparisons. Toxicity was assessed by Common Terminology Criteria for Adverse Events version 4.03.

RESULTS: Nine women with 10 breast cancers were evaluated. Four patients had left-sided cancer, two had prior radiation, and eight had permanent reconstruction. Eight were treated to supraclavicular nodes, three to axillary nodes, and three to internal mammary nodes. Median dose was 50.4 Gy (range: 49.5–60.4 Gy).

A total of 7 3D conformal plans and 3 IMRT plans were compared with the 10 proton plans. There were no differences in planning target volume (PTV) coverage (P ≥ .07). Proton median heart mean dose and V5 were 71 cGy and 2.4%, respectively, compared with 286 cGy (P = .005) and 7.6% (P = .007) for photons. Median mean left ventricle dose was 0.3 cGy compared with 285.2 cGy (P = .005), respectively. Proton median ipsilateral lung mean dose, V5, and V20 were 888 cGy, 30%, and 19% compared with 1,905 cGy (P = .007), 64% (P = .005), and 37% (P = .007) for photons.

Median follow-up was 10.4 months. All acute toxicity was grade ≤ 2. At 48 weeks, there was one grade 4 skin toxicity after a boost to 60.4 Gy. There have been no local recurrences.

CONCLUSIONS: Protons for PMRT, particularly in cases of challenging anatomy, result in decreased dose to normal structures compared with photon plans, with acceptable acute toxicity. Dose escalation after DS-PT should be used with caution to avoid skin toxicity.

Proceedings of the 98th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(S002) A 15-Year Review of Radiation Therapy for Keloids at Two Institutions
(S003) Single-Fraction Radiation Therapy for the Treatment of Multiple Myeloma Bony Metastases Provides Pain Control and Decreases Time to Chemotherapy
(S001) Prognostic Value of Pretreatment Serum Inflammatory Markers in Patients Receiving Radiation Therapy for Oropharyngeal Cancer
(S004) Trend in Second Malignancy Risk for Head and Neck Cancer With Increased Utilization of IMRT: Analysis of SEER Database
(S005) Comparison of Legal Needs of a Group of Patients With Cancer: Economic and Geographic Factors
(S006) Mission Improvement: Lessons From Initiating a Resident-Led Quality Improvement Project on Smoking Cessation at a County Hospital
(S007) Results of a Phase II Trial Using Cetuximab Plus Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
(S008) The Effect of Simulation and Treatment Delays for Patients With Oropharyngeal Cancer Receiving Definitive Radiation Therapy in the Era of Risk Stratification Using Smoking and Human Papilloma Virus Status
(S009) Intensity-Modulated Radiation Therapy With Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on Three-Year Toxicity
(S011) Comparative Study Between Ileal Conduit and Indiana Pouch After Cystectomy for Patients With Carcinoma of Urinary Bladder
(S010) Computed Tomography–Assessed Measures of Bone Mineral Density and Muscle Mass as Predictors of Survival in Men With Prostate Cancer
(S012) Quantitative Imaging to Evaluate the Malignant Potential of Pancreatic Cysts
(S013) Spine Stereotactic Radiosurgery With Concurrent Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
(S014) The Impact of Radiation Therapy on Survival in Surgically Resected, High-Risk Patients With Ampullary Adenocarcinoma: A Population-Based Analysis
(S016) The Impact of Stereotactic Body Radiation Therapy on Overall Survival in Patients With Locally Advanced Pancreatic Cancer
Recent Videos
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
Related Content